Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 2/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 5/20 | 0.38 |
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9289339 | 0.96 | ADH1A (0.46) | ADH1AADH1CHTR1DHTR1BDRD3 | |
| SCHEMBL15865807 | 0.83 | DRD3 (0.48) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL18602764 | 0.81 | ADH1C (0.35) | ADH1AADH1C | |
| SCHEMBL516016 | 0.80 | ADH1A (0.52) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL24693443 | 0.78 | ADH1A (0.38) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL15342472 | 0.78 | DRD3 (0.40) | HTR1DDRD3DRD2DRD4HTR1A | |
| SCHEMBL516269 | 0.78 | ADH1A (0.54) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL22541111 | 0.78 | ADH1A (0.54) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL11073680 | 0.78 | ADH1A (0.54) | ADH1AADH1CDRD3DRD2DRD4 | |
| Hydrochloric Acid SCHEMBL27846052 | 0.78 | CYP1A2 (0.45) | ADH1AADH1CDRD3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | ADH1A 3385/4885ADH1C 4184/4885HTR1D 3496/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | ADH1A 3385/4885ADH1C 4184/4885HTR1D 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.